ScreenerHero

XTLBXTL Biopharmaceuticals Ltd.

NAS · US · Healthcare · Biotechnology · xtlbio.com
2.780USDMkt Cap: 6.83M $P/E: —

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. The company's lead drug candidate is hCDR1,…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap6.83M $
Enterprise Value6.71M $
Revenue (TTM)—
Gross Profit0 $
Net Income (TTM)-6.97M $
Revenue/Share—
Last Price2.780 USD
Fiscal Year EndDec 2025
MR QuarterDec 2025
Employees4
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)—
PEG2.27
EV/EBITDA-5.30
EV/Revenue—
P/S—
P/B—
EPS (TTM)-1.44
EPS (Forward)—
52W Range
—
52W High2.780 USD
52W Low2.780 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE2743.70%
ROA-4198.19%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-1.02M $
CapEx (TTM)—
FCF Margin—
FCF Yield-30.97%
Net Debt-76.00K $
Net Debt/EBITDA0.06
Balance Sheet
Debt/Equity-1.06
Current Ratio0.40
Quick Ratio0.18
Book Value/Sh0.0000 USD
Cash/Share0.0310 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateFeb 10, 2017
Splits
Last Split1:4
Split DateMar 25, 2026
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.2.46M
Float1.50M
Insiders21.44%
Institutions0.21%
Short Interest
Short Ratio0.1d
Short % Float1.33%
Short % Out.1.00%
Shares Short24.56K
Short (prev mo.)9.36K
Technical
SMA 502.751 (+1.1%)
SMA 2002.988 (-7.0%)
Beta0.46
S&P 52W Chg21.00%
Avg Vol (30d)427
Avg Vol (10d)17.30K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—